Table 2.
Significant results for response at three months and development of immune-related adverse events for the first- and further-line patient groups (complete list of results is presented in Tables S3–S6).
| Univariate Methods | Multivariate Methods | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariate Logistic Regressions | Additional Tests | Classification Random Forest | ||||||||
| Patient Group | Response Variable | Predictor | Estimate (OR) | 95% CI | Raw p-Value (LR/Fisher) | Adjusted p-Value (Holm) | Raw p-Value (Wilcoxon) | Adjusted p-Value (Holm) | Raw Impurity Importance p-Value (RF) | Adjusted p-Value (Holm) |
| Further Line | Response3mt | Basophils (0.01 G/l) | 1.3258 | (1.1017,1.6152) | 0.0027 | 0.0453 | 0.0014 | 0.001 | 0.0177 | 0.2832 |
| Eosinophils (0.01 G/l) | 1.0227 | (1.0032,1.0446) | 0.0215 | 0.3443 | 0.0446 | 0.2679 | 0.0978 | 1 | ||
| Steroids: TRUE | 2.3571 | (1.0547,5.4146) | 0.0438 | 0.6564 | - | - | 0.0515 | 0.7725 | ||
| irAE | Basophils (0.01 G/l) | 1.3108 | (1.0849,1.6008) | 0.0049 | 0.0839 | 0.0112 | 0.0781 | 0.0040 | 0.056 | |
| First Line | irAE | Monocytes (1 G/l) | 0.4011 | (0.0652,1.5982) | 0.2167 | 1 | 0.1849 | 1 | 0.0235 | 0.329 |
OR: odds ratio; LR: likelihood ratio; RF: random forest.